enGene Holdings Inc. Common Stock

NasdaqCM ENGN

enGene Holdings Inc. Common Stock Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending October 31, 2024: USD 265.72 M

enGene Holdings Inc. Common Stock Net Cash Used Provided By Financing Activities is USD 265.72 M for the Trailing 12 Months (TTM) ending October 31, 2024, a 208.44% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • enGene Holdings Inc. Common Stock Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending October 31, 2023 was USD 86.15 M.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
SV Wall Street
NasdaqCM: ENGN

enGene Holdings Inc. Common Stock

CEO Mr. Ronald H. W. Cooper
IPO Date Feb. 1, 2022
Location Canada
Headquarters 7171 Rue Frederick Banting
Employees 31
Sector Healthcare
Industries
Biotechnology
Description

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

StockViz Staff

February 6, 2025

Any question? Send us an email